Clinical trial
Vincristine, Dactinomycin, and Cyclophosphamide in Treating Patients With…
NCT00245089 · Japan Rhabdomyosarcoma Study Group, Other · Unknown status
Key facts
| NCT number | NCT00245089 |
|---|---|
| Title | Vincristine, Dactinomycin, and Cyclophosphamide in Treating Patients With Embryonal Rhabdomyosarcoma |
| Official title | Phase II Trial of VAC2.2/VA Therapy for Low-Risk B Group Patients With Rhabdomyosarcoma |
| Lead sponsor | Japan Rhabdomyosarcoma Study Group, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma |
| Intervention type | Biological, Drug |
| Interventions | dactinomycin, cyclophosphamide, vincristine sulfate |
| Enrollment | 41 |
| Start date | May 1, 2004 |
| Primary completion | Apr 1, 2011 |
| First posted | Oct 27, 2005 |
| Last update posted | Aug 12, 2013 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: